EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Agenus's enterprise value is $122.8 Mil.
Agenus's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-145.9 Mil. Therefore, Agenus's EV-to-EBITDA for today is -0.84.
The historical rank and industry rank for Agenus's EV-to-EBITDA or its related term are showing as below:
AGEN'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -10.52 Med: -3.87 Max: 15.95
Current: -0.84
During the past 13 years, the highest EV-to-EBITDA of Agenus was 15.95. The lowest was -10.52. And the median was -3.87.
AGEN's EV-to-EBITDA is ranked worse than 100% of 472
companies
in the Biotechnology industry
Industry Median: 9.005
vs AGEN: -0.84
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-23), Agenus's stock price is $6.20.
Agenus's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-14.000. Therefore, Agenus's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Agenus EV-to-EBITDA Historical Data
The historical data trend for Agenus's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Agenus Annual Data
Trend
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
EV-to-EBITDA
-7.98
-4.88
13.17
-3.78
-2.33
Agenus Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
EV-to-EBITDA
-3.78
-2.30
-2.70
-2.12
-2.33
Competitive Comparison
For the Biotechnology subindustry, Agenus's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Agenus EV-to-EBITDA Distribution
For the Biotechnology industry and Healthcare sector, Agenus's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Agenus's EV-to-EBITDA falls into.
Agenus's current Enterprise Value is $122.8 Mil.
Agenus's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-145.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Agenus (NAS:AGEN) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Agenus's share price for today is $6.20.
Agenus's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-14.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Agenus's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AGEN has been successfully added to your 